Zai Lab Ltd
NASDAQ:ZLAB

Watchlist Manager
Zai Lab Ltd Logo
Zai Lab Ltd
NASDAQ:ZLAB
Watchlist
Price: 18.58 USD -1.28% Market Closed
Market Cap: 1.8B USD

Operating Margin

-6.6%
Current
Improving
by 7.9%
vs 3-y average of -14.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-6.6%
=
Operating Income
$-227m
/
Revenue
$441.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-6.6%
=
Operating Income
$-227m
/
Revenue
$441.6m

Peer Comparison

Country Company Market Cap Operating
Margin
CN
Zai Lab Ltd
HKEX:9688
15.9B HKD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.5B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 77% of companies in China
Percentile
23nd
Based on 8 544 companies
23nd percentile
-6.6%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

Zai Lab Ltd
Glance View

Market Cap
1.8B USD
Industry
Biotechnology

Zai Lab Ltd. is an innovative player in the biotech and pharmaceutical landscape, emerging from China with ambitions that stretch globally. Founded in 2013, the company has quickly built a robust portfolio, focusing on oncology, autoimmune disorders, infectious diseases, and neuroscience. Zai Lab has established itself with a hybrid business model that intertwines the agility of a biotech startup with the strategic partnerships of a mature pharmaceutical company. This approach has allowed it to localize and expedite the development of cutting-edge therapeutics for the Chinese market while simultaneously building a presence in international markets. What sets Zai Lab apart is its keen ability to in-license late-stage pharmaceutical assets from global partners, significantly cutting down on the time and resources typically required for new drug development. The company generates revenue primarily by commercializing these in-licensed drugs in China and neighboring regions. Zai Lab has also expanded its revenue streams through co-development deals, wherein it collaborates with global pharmaceutical giants. This involves sharing research and development costs, thus reducing upfront investment while simultaneously broadening its pipeline. Furthermore, Zai Lab's financial success is bolstered by its strong market position in several key therapeutic areas, driving growth and reinforcing its status as a bridge between international drug innovation and the Chinese healthcare sector. With a focus on rapid commercialization and strong partnerships, Zai Lab continues to blaze a trail in the biopharma industry, well-suited for navigating both domestic and international markets.

ZLAB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-6.6%
=
Operating Income
$-227m
/
Revenue
$441.6m
What is Zai Lab Ltd's current Operating Margin?

The current Operating Margin for Zai Lab Ltd is -6.6%, which is above its 3-year median of -14.5%.

How has Operating Margin changed over time?

Over the last 3 years, Zai Lab Ltd’s Operating Margin has increased from -34.1% to -6.6%. During this period, it reached a low of -34.1% on Aug 30, 2022 and a high of -6.6% on Oct 30, 2025.

Back to Top